Associations Between Etiologic Factors and Mortality After Endometrial Cancer Diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 Trial

Overview

Journal Gynecol Oncol

Date 2015 Sep 6

PMID 26341710

Citations 11

Authors

Ashley S Felix

D Scott McMeekin

David Mutch

Joan L Walker

William T Creasman

David E Cohn

Shamshad Ali

Richard G Moore

Levi S Downs

Olga B Ioffe

Kay J Park

Mark E Sherman

Louise A Brinton

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have analyzed relationships between risk factors for endometrial cancer, especially with regard to aggressive (non-endometrioid) histologic subtypes, and prognosis. We examined these relationships in the prospective NRG Oncology/Gynecologic Oncology Group 210 trial.

Methods: Prior to surgery, participants completed a questionnaire assessing risk factors for gynecologic cancers. Pathology data were derived from clinical reports and central review. We used the Fine and Gray subdistribution hazards model to estimate subhazard ratios (HRs) and 95% confidence intervals (CIs) for associations between etiologic factors and cause-specific subhazards in the presence of competing risks. These models were stratified by tumor subtype and adjusted for stage and socioeconomic status indicators.

Results: Median follow-up was 60months after enrollment (range: 1day-118months). Among 4609 participants, a total of 854 deaths occurred, of which, 582 deaths were attributed to endometrial carcinoma. Among low-grade endometrioid cases, endometrial carcinoma-specific subhazards were significantly associated with age at diagnosis (HR=1.04, 95% CI=1.01-1.06 per year, P-trend) and BMI (class II obesity vs. normal BMI: HR=2.29, 95% CI=1.06-4.98, P-trend=0.01). Among high-grade endometrioid cases, endometrial carcinoma-specific subhazards were associated with age at diagnosis (HR=1.05, 95% CI=1.02-1.07 per year, P-trend<0.001). Among non-endometrioid cases, endometrial carcinoma-specific subhazards were associated with parity relative to nulliparity among serous (HR=0.55, 95% CI=0.36-0.82) and carcinosarcoma cases (HR=2.01, 95% CI=1.00-4.05).

Discussion: Several endometrial carcinoma risk factors are associated with prognosis, which occurs in a tumor-subtype specific context. If confirmed, these results would suggest that factors beyond histopathologic features and stage are related to prognosis. ClinicalTrials.gov Identifier: NCT00340808.

Citing Articles

The Expression and Amplification of HER2 Has a Significant Impact on the Prognosis of Endometrial Carcinoma in Korean Patients.

Kim W, Yang E, Jang E, Lee A, So K, Shim S J Clin Med. 2024; 13(8).

PMID: 38673431 PMC: 11050345. DOI: 10.3390/jcm13082158.

Role of miR‑181a‑5p in cancer (Review).

Li J, Shen J, Zhao Y, Du F, Li M, Wu X Int J Oncol. 2023; 63(4).

PMID: 37539738 PMC: 10552769. DOI: 10.3892/ijo.2023.5556.

Machine learning-based neddylation landscape indicates different prognosis and immune microenvironment in endometrial cancer.

Li Y, Niu J, Wang Y Front Oncol. 2023; 13:1084523.

PMID: 36910623 PMC: 9992729. DOI: 10.3389/fonc.2023.1084523.

Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma.

Wu Z, Wang Q, Liu X, Zheng J, Ji L, Li X J Oncol. 2022; 2022:8998493.

PMID: 36281289 PMC: 9587907. DOI: 10.1155/2022/8998493.

Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.

McVicker L, Cardwell C, Edge L, McCluggage W, Quinn D, Wylie J BMC Cancer. 2022; 22(1):427.

PMID: 35439978 PMC: 9019948. DOI: 10.1186/s12885-022-09510-7.

References

Munstedt K, Wagner M, Kullmer U, Hackethal A, Franke F . Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control. 2008; 19(9):909-16. DOI: 10.1007/s10552-008-9152-7. View

Ahmed A, Zamba G, DeGeest K, Lynch C . The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002. Gynecol Oncol. 2008; 111(1):35-40. DOI: 10.1016/j.ygyno.2008.06.026. View

Zaino R . FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol. 2008; 28(1):1-9. DOI: 10.1097/PGP.0b013e3181846c6d. View

Kang S, Lee J, Lee J, Kim J, Cho C, Kim S . A Web-based nomogram predicting para-aortic nodal metastasis in incompletely staged patients with endometrial cancer: a Korean Multicenter Study. Int J Gynecol Cancer. 2014; 24(3):513-9. DOI: 10.1097/IGC.0000000000000090. View

Benedetti Panici P, Basile S, Salerno M, Di Donato V, Marchetti C, Perniola G . Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 2013; 210(4):363.e1-363.e10. DOI: 10.1016/j.ajog.2013.12.025. View

Gunderson C, Java J, Moore K, Walker J . The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014; 133(1):23-7. DOI: 10.1016/j.ygyno.2014.01.041. View

Ko E, Walter P, Clark L, Jackson A, Franasiak J, Bolac C . The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol. 2014; 133(1):28-32. DOI: 10.1016/j.ygyno.2014.01.032. View

AlHilli M, Mariani A, Bakkum-Gamez J, Dowdy S, Weaver A, Peethambaram P . Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014; 133(3):485-93. PMC: 4405150. DOI: 10.1016/j.ygyno.2014.03.567. View

Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney D . Impact of comorbid conditions on survival in endometrial cancer. Am J Clin Oncol. 2012; 37(2):131-4. DOI: 10.1097/COC.0b013e318277d5f4. View

10.

Ruterbusch J, Ali-Fehmi R, Olson S, Sealy-Jefferson S, Rybicki B, Hensley-Alford S . The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am J Obstet Gynecol. 2014; 211(6):627.e1-9. PMC: 4253020. DOI: 10.1016/j.ajog.2014.06.036. View

11.

Albrektsen G, Heuch I, Wik E, Salvesen H . Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer. 2009; 19(4):665-9. DOI: 10.1111/IGC.0b013e3181a3e1bf. View

12.

Albrektsen G, Heuch I, Wik E, Salvesen H . Prognostic impact of parity in 493 uterine sarcoma patients. Int J Gynecol Cancer. 2009; 19(6):1062-7. DOI: 10.1111/IGC.0b013e3181aaa950. View

13.

Orgeas C, Hall P, Wedren S, Dickman P, Czene K . The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients. Eur J Cancer. 2009; 45(17):3064-73. PMC: 2783257. DOI: 10.1016/j.ejca.2009.05.012. View

14.

Abu-Rustum N, Zhou Q, Gomez J, Alektiar K, Hensley M, Soslow R . A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2009; 116(3):399-403. PMC: 3870336. DOI: 10.1016/j.ygyno.2009.11.027. View

15.

Jeong N, Lee J, Lee J, Kim J, Cho C, Kim S . Role of body mass index as a risk and prognostic factor of endometrioid uterine cancer in Korean women. Gynecol Oncol. 2010; 118(1):24-8. DOI: 10.1016/j.ygyno.2010.03.001. View

16.

Mauland K, Trovik J, Wik E, Raeder M, Njolstad T, Stefansson I . High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011; 104(6):921-6. PMC: 3065282. DOI: 10.1038/bjc.2011.46. View

17.

Crosbie E, Roberts C, Qian W, Swart A, Kitchener H, Renehan A . Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2011; 48(6):853-64. DOI: 10.1016/j.ejca.2011.10.003. View

18.

Kondalsamy-Chennakesavan S, Yu C, Kattan M, Leung Y, Sykes P, Nascimento M . Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol. 2012; 125(3):520-5. DOI: 10.1016/j.ygyno.2012.02.022. View

19.

Ward K, Shah N, Saenz C, McHale M, Alvarez E, Plaxe S . Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012; 126(2):176-9. DOI: 10.1016/j.ygyno.2012.04.013. View

20.

McConechy M, Ding J, Cheang M, Wiegand K, Senz J, Tone A . Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012; 228(1):20-30. PMC: 3939694. DOI: 10.1002/path.4056. View